Fecal Matter Transplant (FMT): An Emerging Therapy for IBD

Watch the video to learn about the use of Fecal Microbiota Therapy (FMT) as a treatment for inflammatory bowel disease (IBD), including advancements in research studies from the IMAGINE Network supported by Crohn's and Colitis Canada.  


Usha Chauhan (N.P.) is an Adult Nurse Practitioner at Hamilton Health Sciences, McMaster University Medical Centre in the Digestive Disease clinic, and Assistant clinical professor with the School of Nursing at McMaster University. She is a steering committee member of the Canadian IBD (CANIBD) nurses, and Crohn's and Colitis Canada's Scientific Medical Advisory Council (SMAC). In 2017, Usha was awarded the CANIBD-research grant to investigate patients’ perceptions of Fecal Microbiota Therapy for the treatment of IBD. 
Melanie Wolfe is a Research Associate, certified CCRP at McMaster University Medical Centre, working in the Farncombe Family Digestive Health Research Institute specializing in Fecal Microbial Transplant. She has worked 24 years in the Gastroenterology, completing numerous clinical trials. Melanie was nominated in 2004 and 2005 for McMaster University Presidents Award for Outstanding Service- IDRP (Intestinal Disease Research Program).


  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest